Is AVXL or BBOT more undervalued in 2026?

CirclFi compares Anavex Life Sciences Corp. (AVXL) and BridgeBio Oncology Therapeutics (BBOT) using 13 institutional-grade valuation models. AVXL has a Quality of Company score of 4.3/10 while BBOT scores 6.2/10.

Which is a better buy — AVXL or BBOT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do AVXL and BBOT valuations compare?

AVXL at $2.94 and BBOT at $8.84 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

AVXL vs BBOT Valuation Comparison 2026 — Intrinsic Value Analysis

AVXL

Biotechnology

Anavex Life Sciences Corp.

Quality

4.3

out of 10

Value Trap

SAFE

Price

$2.94

Last close

Models

10/13

Active

BBOT

Biotechnology

BridgeBio Oncology Therapeutics

Quality

6.2

out of 10

Value Trap

—

Price

$8.84

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	AVXL Fair Value	AVXL Upside	BBOT Fair Value	BBOT Upside
Bayesian DCF	Intrinsic	$1.56	-46.8%	$2.70	-69.5%
Earnings Power Value	Intrinsic	$1.52	-54.1%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.69	-42.6%	$3.92	-55.6%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for AVXL vs BBOT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AVXL vs BBOT — Which Stock Is More Undervalued?

BBOT scores higher with a 6.2/10 quality rating vs AVXL's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Anavex Life Sciences Corp. (AVXL) and BridgeBio Oncology Therapeutics (BBOT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AVXL currently trades at $2.94 with a QOC of 4.3/10, while BBOT trades at $8.84 with a QOC of 6.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).